| 产品介绍 |
Zelenirstat(PCLX-001); first-in-class daily oral treatment for blood and solid tumor cancers in Phase 2.Zelenirstat is a small molecule N-myristoyltransferase inhibitor (NMTi) which binds in the active site, inhibiting myristoylation.Gene expression signature identifies DLBCL and AML among the most zelenirstat-sensitive blood cancers, and colorectal and ovarian cancers (represented in long-term Phase 1 patients) among the most zelenirstat-sensitive solid tumor cancers.
|
微信公众号
